An investment firm and incubator is focused on biotechnology and healthcare. The firm prefers to participate in early-stage and Seed financings as well as later-stage and pre-IPO rounds. The firm typically makes a limited number of investments per year, with initial allocation sizes generally ranging from $500K to $5M for early-stage opportunities and approximately $2M to $10M for later-stage investments. The firm utilizes flexible capital structures on a case-by-case basis and has experience with both equity investments and convertible loans. While the firm primarily invests in U.S.-based companies, the firm is open to evaluating opportunities globally.
The firm is primarily interested in biotechnology therapeutics and medical technology. The firm considers a wide range of therapeutic modalities and has particular expertise in molecule development, while generally avoiding medical devices and digital health. The firm will evaluate diagnostic opportunities but prefers a focus on genomics and biomarker-based diagnostics. The firm considers therapeutics at the preclinical stage through Phase I, Phase II, and Phase III clinical development, as well as medical technology and diagnostics that are in development or clinical stages. The firm is disease-agnostic and evaluates opportunities across indications, with prior experience in oncology and autoimmune-related technologies.
From a company and management team perspective, the firm prefers to partner with experienced management teams that are fully dedicated to their technology and company. The firm is an active investor and may take a board seat on a case-by-case basis depending on investment size. The firm is open to acting as both a lead investor and a co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment